A Prospective, Nonrandomized, no Placebo-Controlled, Phase I/II Clinical Trial Assessing the Safety and Efficacy of Intramuscular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Patients With Sev
Ra JC., Jeong EC., Kang SK., Lee SJ., Choi KH.
Clinical Trial with a reported sample of 17 on Peripheral Artery Disease, published in Cell Med (2016) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Cell Med (2016)
- Country
- United States
- Reported sample size
- 17
- Source database
- PubMed
- PMID
- 28713639
- PMCID
- PMC5509019
- DOI
- 10.3727/215517916X693069
- Citations
- 16
Abstract (original English)
Buerger's disease is a rare and severe disease affecting the blood vessels of the limbs. Adipose tissue-derived mesenchymal stem cells (ADSCs) have the potential to cure Buerger's disease when developed as a stem cell drug. In the present study, we conducted a prospective, nonrandomized, no placebo-controlled, phase I/II clinical trial with a 2-year follow-up questionnaire survey. A total of 17 patients were intramuscularly administered autologous ADSCs at a dose of 5 million cells/kg. The incidence of adverse events (AEs), adverse drug reaction (ADR), and serious adverse events (SAEs) was monitored. No ADRs and SAEs related to stem cell treatment occurred during the 6-month follow-up. In terms of efficacy, the primary endpoint was increase in total walking distance (TWD). The secondary endpoint was improvement in rest pain, increase in pain-free walking distance (PFWD), toe-brachial pressure index (TBPI), transcutaneous oxygen pressure (TcPO 2 ), and arterial brachial pressure index (ABPI). ADSCs demonstrated significant functional improvement results including increased TWD, PFWD, and rest pain reduction. No amputations were reported during the 6-month clinical trial period and in the follow-up questionnaire survey more than 2 years after the ADSC injection. In conclusion, intramuscular injection of ADSCs is very safe and is shown to prompt functional improvement in patients
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Cellular therapy for the peripheral arterial disease treatment: Protocol for a systematic review and meta-analysis
Meta-analysis on Peripheral Artery Disease, published in PLoS One (2025) — summary generated from the PubMed abstract.
- 2025
PLoS One1 citations - Level ASystematic ReviewPubMed
The Efficacy of Stem Cells in Wound Healing: A Systematic Review.
Systematic Review on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in Int J Mol Sci (2024) — summary generated from the PubMed abstract.
- 2024
Int J Mol Sci60 citations - Level AMeta-analysisEurope PMC
The Immune-Centric Revolution Translated into Clinical Application: Peripheral Blood Mononuclear Cell (PBMNC) Therapy in Diabetic Patients with No-Option Critical Limb-Threatening Ischemia (NO-CLTI)-Rationale and Meta-An
Meta-analysis on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in J Clin Med (2024) — summary generated from the PubMed abstract.
- 2024
J Clin Med2 citations - Level ASystematic ReviewEurope PMC
A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia
Systematic Review on Peripheral Artery Disease, published in J Vasc Surg (2022) — summary generated from the PubMed abstract.
- 2022
J Vasc Surg23 citations - Level AMeta-analysisEurope PMC
Autologous Stem Cell Therapy for Chronic Lower Extremity Wounds: A Meta-Analysis of Randomized Controlled Trials
Meta-analysis with a reported sample of 1096 on Peripheral Artery Disease, Chronic Wound, published in Cells (2021) — summary generated from the PubMed abstract.
- 2021
- n = 1096
Cells19 citations - Level ARandomized Controlled TrialPubMed
Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF).
Randomized Controlled Trial with a reported sample of 114 on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in Stem Cell Res Ther (2019) — summary generated from the PubMed abstract.
- 2019
- n = 114
Stem Cell Res Ther57 citations